0000000000768502
AUTHOR
Umberto Ricardi
Deauville score evaluationof PET2 positive patients included in the H10 trial
IF 7.704 (2017)Communication donnée lors du 31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Dusseldorf, Germany, du 13 au 17 octobre 2018; International audience
Incidence, survival and prevalence of myeloid malignancies in Europe.
Abstract Background The Surveillance of Rare Cancers in Europe (RARECARE) project aims at increasing knowledge of rare cancers in Europe. This manuscript describes the epidemiology of myeloid malignancies (MMs), taking into account the morphological characterisation of these tumours. Methods We used data gathered by RARECARE on cancer patients diagnosed from 1995 to 2002 and archived in 64 European population-based cancer registries, followed up to 31st December 2003 or later. Results The overall annual crude incidence of MMs was 8.6 per 100,000. Acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPN) were most common, with incidence rates of 3.7 and 3.1 per 100,000 year respec…